ClinicalTrials.gg
RecruitingNCT06364267BabyTearsUpdated Nov 18, 2025

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

A Phase 2 interventional study of Tamoxifen 10 MG and Exemestane 25 MG in Breast Cancer, sponsored by Andrea DeCensi. Recruiting at 1 site in Italy. Open to female participants. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Andrea DeCensi · Phase 2, Interventional, and Prevention

How we know · 4 judgments

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies testing tamoxifen in Breast Neoplasms — 16 open to participants now, 30 under way, 9 of them phase 3. Tamoxifen · Breast Neoplasms.

Planned enrollment
67th of 126
140 · median 169
Started
2025
with 3 others
Phase 2
52 of 133
9 open now
Primary completion
2027-01
later than 18 of 29 live
Registered
127th of 133
by date
Lead sponsor
2 of 133
Andrea DeCensi

Among the 133 studies testing tamoxifen in Breast Neoplasms, this one is the 67th largest by planned enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2025, is one of 52 in phase 2, reaches primary completion later than 18 of the 29 other live ones, and was the 127th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 133 studies testing tamoxifen in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About tamoxifen

Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies testing tamoxifen in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.

Read the detailed description

This is a multicenter, randomized, double blind phase II trial.

Eligible patients will be randomized in a 1:1 ratio to:

ARM 1: BabyEXE Arm, 25 mg eod, typically every odd day of the monthly calendar for 12 monthsor unless progression, SAE, medical decision, patient withdrawal occur.

ARM 2: BabyTAM Arm, 10 mg eod, typically every odd day of the monthly calendar for 12 months or unless progression, SAE, medical decision, patient withdrawal occur.

Blinding will be guaranteed by over-encapsulation of active tablet agents with an AA capsule in a 6-month bottle.

In both arms, treatment should begin within 30 days from randomization. Exemstane and Tamoxifen will be provided for free by the Study Sponsor.

After study completion, participants will be unblinded and treated according to local guidelines. Clinical visit will be performed every 6 months (±14 days) with physical examination vital signs and weight and girth measurement, ECOG PS, MENQOL questionnaire (0, 6, 12 months), review of self-reported compliance, concomitant medications, AEs assessment, and physical exam. Telephone/video contact may be allowed at 3 and 9 months, whereas baseline, 6 months and 12 months visits are necessary for blood collection and biomarker assessment. Blood serum for centralized storage at IEO, Milan, Italy, will be collected at different time points.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer, menopause, exemestane, tamoxifen, MenQol, Low dose
  • babytam, babyexe
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post- menopausal state in women not using hormonal or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

    Any of the following criteria must be met:

    1. Recent (within 12 months from date of consent form signature) histologic diagnosis of ER+ve (>5%) DCIS (patients with DCIS should have undergone breast-conserving therapy i.e. lumpectomy to remove the tumor with negative surgical margins followed by radiotherapy) or diagnosis within 3 years of HRL (ADH, LCIS, ALH), or:
    2. At least 3% breast cancer risk at 5 years (or 5% risk at 10yrs) per one of the following risk models: the Breast Cancer Surveillance Consortium risk calculator V3 or Tyrer-Cuzick model V8 or:
    3. Known carriers of a germline pathogenic/likely pathogenetic variant in the following moderate penetrance genes (CHEK2 or ATM), or women with chest wall irradiation before age of 30 years.
  2. - Performance Status (ECOG-PS) 0-1.
  3. Able to swallow oral medications.
  4. Participants with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial. Specifically, all cancers diagnosed since 3 years or longer except for breast and endometrial are eligible.
  5. Ability to understand and the willingness to sign a written document.
  6. Mammography performed up to 6 months before the trial consent form signature.
  7. DEXA performed up to 12 months before the trial consent form signature.
  8. Patients with ≥ 10 years.
  9. Patients with normal liver function tests and blood cell count.
  10. Negative gynaecological examination performed up to 6 months before the trial consent form signature.

Exclusion criteria

Exclusion Criteria:

  1. Pre/perimenopausal women
  2. History of DVT or PE.
  3. Endometrial cancer.
  4. Macular disorders.
  5. Inability to comply with study procedures.
  6. Prior use of antiestrogens within 12 months from the date of the trial consent form signature.
  7. Use of hormone replacement therapy (HRT) within 3 months from the date of the trial consent form signature.
  8. Severe osteoporosis (T score ≤ 2.5 at either spine or hip), or recent vertebral fracture (within 6 months) not treated with zolendronic acid or denosumab.
  9. Use of terbinafine, quinidine, cinacalcet, rifampicin, phenytonin, carbamazepine, phenobarbital, and St. John's wort, warfarin, erythromycin, cyclosporin, nifepidine and any concomitant coumarin-type anticoagulant therapy.
  10. Patients with moderate or severe renal impairment.
  11. Patients with a known to study drugs.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    ARM 1

    BabyEXE Arm, 25 mg eod, typically every odd day of the monthly calendar for 12 months.

    Drug: Exemestane 25 MG

  • Experimental
    ARM 2

    BabyTAM Arm, 10 mg eod, typically every odd day of the monthly calendar for 12 months

    Drug: Tamoxifen 10 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Quality of life MEnQol

    The primary endpoint is the difference between arms in the score of overall domain of MENQOL after 12 months of treatment.

    Time frame: 12 months

Secondary outcomes

  1. Sex hormones

    The difference in sex hormones (free estradiol: estradiol/SHBG) and IGF system (IGF-I, IGFBP-3 and their ratio) after 12 months, as surrogate endpoint biomarkers.

    Time frame: 12 months

  2. MenQol score domain

    The difference between arms in the overall MENQOL score domain after 6 months of treatment.

    Time frame: 6 months

  3. Sex hormones

    The difference in sex hormones (free estradiol: estradiol/SHBG) and IGF system (IGF-I, IGFBP-3 and their ratio) after 6 months, as surrogate endpoint biomarkers.

    Time frame: 6 months

  4. Other domains of MenQol

    The difference between arms individual domains of MENQOL (physical, sexual, psychosocial, vasomotor) at 6 and 12 months

    Time frame: 6 and 12 months

  5. Safety profile

    The difference between arms of safety profile according to CTCAE v.5 at 6 and 12 months.

    Time frame: 6 and 12 months

  6. PMAS

    The difference between arms at 6 and 12 months in PMAS, Promise Medication Adherence Scale, a validated tool to measure pill adherence.

    Time frame: 6 and 12 months

  7. BPI

    The difference between arms on BPI Brief Pain Inventory at 6 and 12 months.

    Time frame: 6 and 12 months

  8. Bone biomarker

    The difference between arms in C-telopetide at 6 and 12 months

    Time frame: 6 and 12 months

  9. Customer satisfatcion

    Patient uptake at screening/baseline phase will be measured with a questionnaire including factors related to breast cancer worry and presence of life style risk factors, and participant satisfaction for study explanation.

    Time frame: Screening

  10. Exemestane toxicity

    Toxicity of babyexe in comparison with full dose historical controls treated in the adjuvant setting will also be evaluated

    Time frame: 12 months

Other outcomes

  1. MMG risk score

    Change at 12 months of risk score using an image derived artificial intelligence risk model for digital mammography.

    Time frame: 12 months

  2. MMG density

    Change at 12 months of mammographic density using an image derived artificial intelligence model.

    Time frame: 12 months

  3. HOMA

    Change at 6 and 12 months of HOMA index

    Time frame: 6 and 12 months

  4. Hs-CRP

    Change at 6 and 12 months of hs-CRP

    Time frame: 6 and 12 months

  5. Adipokines

    Change at 6 and 12 months of adipokines (adiponectin and leptin).

    Time frame: 6 and 12 months

  6. Bone density

    Difference between arms in the change in T-score of lumbar spine and femur as measured by DEXA at 12 months.

    Time frame: 12 months

  7. BMI

    Difference between arms at 6 and 12 months in the changes in primary and secondary endpoints by BMI in kg/m\^2

    Time frame: 6 and 12 months

  8. Other biomarkers

    Menopausal symptoms and biomarker levels by serum drug and metabolite levels at 6 and 12 months in each arm. Tamoxifen, 4-OH-tamoxifen, endoxifen, other tamoxifen metabolites, exemestane and 17OH-exemestane will be measured.

    Time frame: 6 and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2027, 15 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 15 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 15, 2024
StartActual
Oct 1, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06364267
Lead sponsor
Andrea DeCensi
Collaborators
Dana-Farber/Brigham and Women's Cancer Center, Herbert Irving Comprehensive Cancer Center, Istituto Europeo di Oncologia, Breast Cancer Research Foundation
Responsible party
Andrea DeCensi (Director of Medicin Department and Oncology Division, Ente Ospedaliero Ospedali Galliera) — Sponsor-investigator
First posted
Apr 15, 2024
Start date
Oct 1, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 18, 2025

Study contacts

Andrea U De Censi, MD
Contact
andrea.decensi@galliera.it
+39.010.563.4501
Davide S Corradengo, SC
Contact
davide.corradengo@galliera.it
+39.010.563.4580
Andrea U De Censi, MD
study chair · Ente Ospedaliero Ospedali Galliera

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamoxifen · Exemestane

Start the discussion